Teva Pharmaceutical Industries Limited · TASE:TEVA

Teva Pharmaceutical Industries — IPO Roadshow (July 2016)

21 slides from Teva Pharmaceutical Industries's IPO roadshow presentation, Jul 13, 2016

  1. Slide 1: 2016-2019 Preliminary Financial Outlook

    Teva Pharmaceutical Industries 2016-2019 Preliminary Financial Outlook July 13, 2016 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Nos. 333-201984 and 333-201984-09 July 13, 2016

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: Important Notice: Teva Pharmaceutical Industries Limited (Teva) has filed a registration statement (including a prospectus) with the SEC for the offering to which this presentation relates. Before you invest, you

  3. Slide 3: 2016-2019 Preliminary Financial Outlook - Agenda

    2016-2019 Preliminary Financial Outlook - Agenda Erez Vigodman, President & CEO Eyal Desheh, Group Executive VP and CFO Q&A with Management Team

  4. Slide 4: Erez Vigodman, President & CEO

    Erez Vigodman, President & CEO

  5. Slide 5: Teva + Actavis Generics: a compelling transaction

    Transform the generics space by combining two of the industry’s best generics companies Cement and broaden our R&D capabilities Enhance Teva’s leadership in an evolving customer landscape Strongly reinforce Teva's strategy Open new possibilities for the company in generics and specialty Accelerate t

  6. Slide 6: Net Revenues Growth

    Net Revenues Growth Net Revenues CAGR 9%, based on mid-point of range $ billions

  7. Slide 7: EBITDA Growth

    EBITDA Growth EBITDA presented on a non-GAAP basis EBITDA CAGR 14%, based on mid-point of range $ billions

  8. Slide 8: Net Income and EPS Growth

    Net Income and EPS Growth EPS ($) 5.42 5.20-5.40 6.00-6.50 6.30-6.90 6.90-7.40 Shares (m) 867 1,021 1,085 1,092 1,099 Net income and EPS presented on a non-GAAP basis Net Income CAGR 14%, based on mid-point of range $ billions

  9. Slide 9: Cash Flow Growth

    Cash Flow Growth 2015A 2016E 2017E 2018E 2019E Free cash flow excluding divestitures $ billions 4.9 4.7-5.2 6.0-6.6 6.7-7.3 7.2-7.8 Divestiture Proceeds $ billions - 2.9 - - - Free cash flow $ billions 4.9 7.6-8.1 6.0-6.6 6.7-7.3 7.2-7.8 Over $25 billion of free cash flow generated from close to the

  10. Slide 10: Synergies and Tax Savings in 2019

    Synergies and Tax Savings in 2019 $ billion 1.4 Tax

  11. Slide 11: Synergies Realization Curve

    Synergies Realization Curve $m, Illustrative only July 2015 Plan July 2016 Plan Jan-20 -300 -600 1,400

  12. Slide 12: Net Total Deal Cost & Financing Implications

    Net Total Deal Cost & Financing Implications $ billions July 2015 July 2016 Deal price 40.5 40.5 Divestiture proceeds 0.4 2.9 Working capital adjustment 0.8 Allergan retained products 0.2 Change in equity value to Allergan 1.5 Total net cost of the deal 40.1 35.1 Actavis Generics net deal financing

  13. Slide 13: Net Debt Evolution

    Net Debt Evolution @ Closing Dec 31, 2016E Dec 31, 2017E Dec 31, 2018E Dec 31, 2019E Net Debt ($b) 34.0 31.8 27.2 21.8 12.7 Net Debt/EBITDA 4.30x 4.14x 2.75x 2.09x 1.14x EBITDA presented on a non-GAAP basis. Debt repayment follows planned bond maturity schedules, prepayment of certain term loans, an

  14. Slide 14: Contribution of the Actavis Generics Deal

    $ billions July 2015 view FY 2016 July 2016 view FY 2017 Actavis EBITDA 2.7 2.6 Net contribution of synergies & divestitures 0.5 0.4 Tax & finance expenses (1.2) (0.9) Depreciation (0.2) (0.2) Deal Contribution to Net Income 1.8 1.9 Contribution of the Actavis Generics Deal EBITDA and Net Income pre

  15. Slide 15: Actavis Generics First-to-Files

    Actavis Generics First-to-Files in the First 4 Months of 2016 20 FTFs posted on FDA website Note: Exclusive FTF sales include products launched in the first 4 months of 2016 (not yet matured), until May 10, 2016. IMS sales for some products are under-reported. Source: FDA Paragraph IV Certifications

  16. Slide 16: Eyal Desheh, Group Executive VP & CFO

    Eyal Desheh, Group Executive VP & CFO

  17. Slide 17: Q2 2016 Financial Outlook Highlights

    Q2 2016 Financial Outlook Highlights Q2 2016 Outlook May 2016 Q2 2016 Outlook July 2016 Revenues $ billions 4.7-4.9 4.9-5.0 Non-GAAP EPS $ 1.16-1.20 1.19-1.22 Weighted average number of shares, in millions 980 980 Cash flow from operations $ billions 1.2-1.3 1.0-1.1

  18. Slide 18: FY 2016 Financial Outlook Highlights

    FY 2016 Financial Outlook Highlights FY 2016 Outlook Revenues $ billions 22.0-22.5 Non-GAAP EPS $ 5.20-5.40 Weighted average number of shares, in millions 1,021 Cash flow from operations $ billions 5.7-6.1

  19. Slide 19: 2016-2019 financial highlights

    2016-2019 financial highlights 2016E 2017E 2018E 2019E Revenues $ billions 22.0-22.5 25.2-26.2 25.8-26.9 26.7-27.8 Operating income $ billions 6.9-7.3 8.9-9.5 9.3-10.1 10.0-10.8 EBITDA $ billions 7.5-7.9 9.5-10.3 10.0-10.8 10.7-11.5 EPS $ 5.20-5.40 6.00-6.50 6.30-6.90 6.90-7.40 Weighted average numb

  20. Slide 20: In summary

    In summary Strong Strategic Fit Strong strategic fit between Teva and Actavis Generics in one of the most attractive industries globally Unparalleled Platform Highly complementary products portfolio and best‐in‐class generics pipeline and R&D capabilities; positioned for growth with ~326 combined pe

  21. Slide 21: Q&A Thank You

    Q&A Thank You

Teva Pharmaceutical Industries — IPO Roadshow (July 2016) on 6ix